Joseph T Dougherty

US Patent:

6613569, Sep 2, 2003

Filed:

Mar 5, 2002

Appl. No.:

09/979681

Inventors:

Joseph P Dougherty - Hampton NJ
Martin E Adelson - Hillsborough NJ
Malvika Kaul - Piscataway NJ
AnnMarie L Pacchia - Piscataway NJ
Yacov Ron - East Brunswick NJ

Assignee:

University of Medicine and Dentistry of New Jersey - New Brunswick NJ

International Classification:

C12N 508

US Classification:

435457, 435 691, 435 693, 4352351, 435236, 4353201, 435366, 435369, 435325, 435440, 435458, 435456, 435377, 435367, 514 44, 536 2372

Abstract:

Novel packaging cell lines for production of lentiviral vectors are disclosed. The cell lines utilize an ecdysone-inducible system for virus production, thereby avoiding the cytotoxic effect of unregulated expression of certain envelope proteins and lentiviral proteins. Various embodiments of the cell lines are disclosed, which are suitable for different purposes that range from in vitro screening assays to gene therapy in vivo.

US Patent:

7337941, Mar 4, 2008

Filed:

Apr 21, 2003

Appl. No.:

10/419520

Inventors:

Raymond J. Kilmer - Lancaster PA, US
Joseph R. Dougherty - Schwenksville PA, US
Robert P. Anthony - Norristown PA, US

Assignee:

Alcoa Inc. - Pittsburgh PA

International Classification:

B23K 31/02
B23K 35/34

US Classification:

228207, 228223, 228224, 148 24

Abstract:

A brazing flux mixture comprised of brazing flux, a polyvinyl butyral resin binder, and an organic solvent which can be applied over an entire aluminum alloy brazing sheet, or can be applied on the brazing sheet only where metallurgical bonds or joints are required, that is sufficiently durable to withstand processing operations and also provides good metallurgical bonds upon brazing.

US Patent:

8247167, Aug 21, 2012

Filed:

Nov 27, 2006

Appl. No.:

12/096245

Inventors:

Joseph P. Dougherty - Milford NJ, US
Sofiya Micheva-Viteva - Los Alamos NM, US
Stuart W. Peltz - Califon NJ, US
Yacov Ron - East Brunswick NJ, US
Annmarie L. Pacchia - Buffalo NY, US

Assignee:

University of Medicine and Dentistry of New Jersey - New Brunswick MA

International Classification:

C12N 7/01
C12N 15/867

US Classification:

435 5, 4352351

Abstract:

Isolated, latently infected T cell lines are provided that can be utilized in high throughput screening to discover compounds capable of activating HIV-I. The T cell lines harbor a latent HIV-I derived vector pro virus, which upon activation expresses a marker for late viral gene expression due to the insertion of the marker gene in the position of HIV-I envelope.

US Patent:

20130040385, Feb 14, 2013

Filed:

Jul 17, 2012

Appl. No.:

13/551257

Inventors:

Joseph P. Dougherty - Milford NJ, US
Sofiya Micheva-Viteva - Los Alamos NM, US
Stuart W. Peltz - Califon NJ, US
Yacov Ron - Califon NJ, US
Annmarie L. Pacchia - Buffalo NY, US

Assignee:

UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY - New Brunswick NJ

International Classification:

C12N 5/10

US Classification:

435325

Abstract:

Isolated, latently infected T cell lines are provided that can be utilized in high throughput screening to discover compounds capable of activating HIV-I. The T cell lines harbor a latent HIV-I derived vector pro virus, which upon activation expresses a marker for late viral gene expression due to the insertion of the marker gene in the position of HIV-I envelope.

US Patent:

56679980, Sep 16, 1997

Filed:

Jun 7, 1995

Appl. No.:

8/477363

Inventors:

Joseph Dougherty - Hampton NJ
Ming-Ling Kuo - Taipei, TW
Natalie Sutkowski - Gloucester MA
Yacov Ron - East Brunswick NJ

Assignee:

University of Medicine and Dentistry of New Jersey - Newark NJ

International Classification:

C12N 510
C12N 1564

US Classification:

4351723

Abstract:

The present invention pertains to a method for efficiently introducing exogenous genes into primary lymphoid cells without drug selection which comprises the steps (a) deriving a retroviral vector and a helper cell combination that will yield a level of virus production in the range from 5. times. 10. sup. 6 to 5. times. 10. sup. 7 units/ml by transfecting a vector into a helper cell followed by selection, isolation of cell clones, and determination of viral titers to identify which virus-producing cell lines produce a virus titer in the range from 5. times. 10. sup. 6 to 5. times. 10. sup. 7 units/ml; (b) isolating a lymphoid cell subpopulation which can repopulate a specific lymphoid lineage or is a long-lived population by treating a suspension of lymphoid cells with a monoclonal antibody which removes undesired lymphoid cells to obtain an enriched lymphoid subpopulation; (c) culturing the enriched lymphoid subpopulation from step (b) with growth factors specific to the lymphoid subpopulation; (d) co-cultivating the lymphoid subpopulation from step (c) with a lawn of irradiated virus-producing cell line from step (a) to produce an infected lymphoid subpopulation; and (e) harvesting the infected lymphoid subpopulation. The invention further relates to a population of transfected lymphocytes, in which greater than about 90% of the lymphocytes contain a provirus.

US Patent:

40666344, Jan 3, 1978

Filed:

Aug 31, 1976

Appl. No.:

5/719304

Inventors:

William H. McGregor - Malvern PA
Joseph J. Dougherty - Drexel Hill PA

Assignee:

American Home Products Corporation - New York NY

International Classification:

C07C10352
A61K 3700

US Classification:

2601125S

Abstract:

High speed liquid chromatography of synthetically produced somatostatin yields somatostatin free from structural artifacts.

US Patent:

56862806, Nov 11, 1997

Filed:

Sep 8, 1994

Appl. No.:

8/302232

Inventors:

Joseph Dougherty - Hampton NJ
Ming-ling Kuo - Piscataway NJ
Natalie Sutkowski - Edison NJ
Yacov Ron - East Brunswick NJ

Assignee:

University of Medicine & Dentistry of New Jersey - Newark NJ

International Classification:

C12N 510
C12N 1564

US Classification:

4351723

Abstract:

The present invention pertains to a method for efficiently introducing exogenous genes into primary lymphoid cells without drug selection which comprises the steps (a) deriving a retroviral vector and a helper cell combination that will yield a level of virus production in the range from 5. times. 10. sup. 6 to 5. times. 10. sup. 7 units/ml by transfecting a vector into a helper cell followed by selection, isolation of cell clones, and determination of viral titers to identify which virus-producing cell lines produce a virus titer in the range from 5. times. 10. sup. 6 to 5. times. 10. sup. 7 units/ml; (b) isolating a lymphoid cell subpopulation which can repopulate a specific lymphoid lineage or is a long-lived population by treating a suspension of lymphoid cells with a monoclonal antibody which removes undesired lymphoid cells to obtain an enriched lymphoid subpopulation; (c) culturing the enriched lymphoid subpopulation from step (b) with growth factors specific to the lymphoid subpopulation; (d) co-cultivating the lymphoid subpopulation from step (c) with a lawn of irradiated virus-producing cell line from step (a) to produce an infected lymphoid subpopulation; and (e) harvesting the infected lymphoid subpopulation.

US Patent:

59069287, May 25, 1999

Filed:

Mar 19, 1996

Appl. No.:

8/586754

Inventors:

Joseph Dougherty - Hampton NJ
Yacov Ron - East Brunswick NJ

Assignee:

University of Medicine and Dentistry of New Jersey - Newark NJ

International Classification:

C12N 1510
C12N 1563
C12N 1586
C12N 510

US Classification:

4351723

Abstract:

The present invention pertains to a method for efficiently introducing exogenous genes into primary lymphoid cells without drug selection which comprises the steps (a) deriving a retroviral vector and a helper cell combination that will yield a level of virus production in the range from 5. times. 10. sup. 6 to 5. times. 10. sup. 7 units/ml by transfecting a vector into a helper cell followed by selection, isolation of cell clones, and determination of viral titers to identify which virus-producing cell lines produce a virus titer in the range from 5. times. 10. sup. 6 to 5. times. 10. sup. 7 units/ml; (b) isolating a lymphoid cell subpopulation which can repopulate a specific lymphoid lineage or is a long-lived population by treating a suspension of lymphoid cells with a monoclonal antibody which removes undesired lymphoid cells to obtain an enriched lymphoid subpopulation; (c) culturing the enriched lymphoid subpopulation from step (b) with growth factors specific to the lymphoid subpopulation; (d) co-cultivating the lymphoid subpopulation from step (c) with a lawn of irradiated virus-producing cell line from step (a) to produce an infected lymphoid subpopulation; and (e) harvesting the infected lymphoid subpopulation. The invention further relates to a population of transfected lymphocytes, in which greater than about 90% of the lymphocytes contain a provirus.